Ann Surg Treat Res.  2022 Aug;103(2):63-71. 10.4174/astr.2022.103.2.63.

Overexpression of FRAT1 protein is closely related to triple-negative breast cancer

Affiliations
  • 1Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
  • 2Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea
  • 3Pathology Center, Seegene Medical Foundation, Seoul, Korea
  • 4Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea

Abstract

Purpose
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis and a lack of targeted therapy. Overexpression of FRAT1 is thought to be associated with this aggressive subtype of cancer. Here, we performed a comprehensive analysis and assessed the association between overexpression of FRAT1 and TNBC.
Methods
First, using different web-based bioinformatics platforms (TIMER 2.0, UALCAN, and GEPIA 2), the expression of FRAT1 was assessed. Then, the expression of the FRAT1 protein and hormone receptors and HER2 status were assessed by immunohistochemical analysis. For samples of tumors with equivocal immunoreactivity, we performed silver in situ hybridization of the HER2 gene to determine an accurate HER2 status. Next, we used the R package and bc-GenExMiner 4.8 to analyze the relationship between FRAT1 expression and clinicopathological parameters in breast cancer patients. Finally, we determined the relationship between FRAT1 overexpression and prognosis in patients.
Results
The expression of FRAT1 in breast cancer tissues is significantly higher than in normal tissue. FRAT1 expression was significantly related to worse overall survival (P < 0.05) and was correlated with these clinicopathological features: T stage, N stage, age, high histologic grade, estrogen receptor status, progesterone receptor status, Her-2 status, TNBC status, basal-like status, CK5/6 status, and Ki67 status.
Conclusion
FRAT1 was overexpressed in breast cancer compared to normal tissue, and it may be involved in the progression of breast cancer malignancy. This study provides suggestive evidence of the prognostic role of FRAT1 in breast cancer and the therapeutic target for TNBC.

Keyword

FRAT1; Prognosis; Triple negative breast neoplasms

Figure

  • Fig. 1 The expression of FRAT1 messenger RNA in Pan-cancer. Human FRAT1 expression levels in different tumor types from TCGA database were determined by TIMER 2.0 (http://timer.cistrome.org). TCGA, The Cancer Genome Atlas; TIMER, Tumor Immune Estimation Resource. ***P < 0.001, **P < 0.01, *P < 0.05.

  • Fig. 2 The expression of FRAT1 messenger RNA in breast cancer. (A) Expression of FRAT1 in breast cancer based on sample types by UALCAN (http://ualcan.path.uab.edu/index.html), P < 0.001. (B) The Expression of FRAT1 in breast cancer tissue and normal tissue generated by GEPIA 2 web (http://gepia2.cancer-pku.cn/#index); TCGA database, P < 0.01. GEPIA, Gene Expression Profiling Interactive Analysis; TCGA,The Cancer Genome Atlas.

  • Fig. 3 Immunohistochemical analysis of FRAT1 expression. (A) Negative reactivity of FRAT1 in the normal ductal and myoepithelial cells (×200). (B) Cytoplasmic and membranous expression of FRAT1 in breast cancer (×400).

  • Fig. 4 Kaplan-Meier survival analysis. Kaplan-Meier survival analysis demonstrated that the group with FRAT1 expression showed significantly worse overall survival than the one without FRAT1 expression.

  • Fig. 5 Relationship between FRAT1 expression and clinicopathological parameters in breast cancer patients. The box plot was retrieved from the Breast Cancer Gene-Expression Miner ver. 4.8 (http://bcgenex.ico.unicancer.fr/BC-GEM/GEM-Accueil.php?js=1). Global significant difference between groups was assessed by Welch t-test to generate P-values, along with the Dunnett-Tukey-Kramer test. ER, estrogen receptor; PR, progesterone receptor; HER2, HER2 receptor; TNBC, triple-negative breast cancer; IHC, immunohistochemistry; mRNA, messenger RNA.

  • Fig. 6 Relationship between FRAT1 messenger RNA expression and clinical outcomes in breast cancer patients in PrognoScan database (http://dna00.bio.kyutech.ac.jp/PrognoScan/index.html). Breast cancer; GSE9893; overall survival; hazard ratio, 1.33 (1.10–1.61), P = 0.010.

  • Fig. 7 Relationship between FRAT1 messenger RNA expression and clinical outcomes in breast cancer patients in R2: Kaplan-Meier scanner. Tumor breast invasive carcinoma; The Cancer Genome Atlas (TCGA); overall survival, P = 0.025.


Reference

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005; 34:405–412. PMID: 15737977.
Article
2. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010; 23 Suppl 2:S60–S64. PMID: 20436504.
Article
3. Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011; 121:3786–3788. PMID: 21965334.
Article
4. Liao C, Zhang Y, Fan C, Herring LE, Liu J, Locasale JW, et al. Identification of BBOX1 as a therapeutic target in triple-negative breast cancer. Cancer Discov. 2020; 10:1706–1721. PMID: 32690540.
Article
5. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; 9(Suppl 2):S73–S81. PMID: 19596646.
Article
6. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012; 30:1879–1887. PMID: 22454417.
Article
7. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol. 2001; 19:311–315. PMID: 11445844.
Article
8. Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan CF, et al. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch. 2011; 459:255–263. PMID: 21818639.
Article
9. Hagen T, Cross DA, Culbert AA, West A, Frame S, Morrice N, et al. FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A. J Biol Chem. 2006; 281:35021–35029. PMID: 16982607.
Article
10. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018; 62:50–60. PMID: 29169144.
Article
11. Guo G, Mao X, Wang P, Liu B, Zhang X, Jiang X, et al. The expression profile of FRAT1 in human gliomas. Brain Res. 2010; 1320:152–158. PMID: 20096670.
Article
12. Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H, Zhou C, et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer. 2006; 94:686–691. PMID: 16479254.
Article
13. Wang Y, Liu S, Zhu H, Zhang W, Zhang G, Zhou X, et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer. 2008; 123:561–568. PMID: 18498136.
Article
14. Zhu K, Guo J, Wang H, Yu W. FRAT1 expression regulates proliferation in colon cancer cells. Oncol Lett. 2016; 12:4761–4766. PMID: 28101222.
Article
15. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68–A77. PMID: 25691825.
16. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509–W514. PMID: 32442275.
Article
17. Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017; 19:649–658. PMID: 28732212.
Article
18. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98–W102. PMID: 28407145.
Article
19. Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G, et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012; 131:765–775. PMID: 21452023.
Article
20. Hashmi AA, Naz S, Hashmi SK, Hussain ZF, Irfan M, Bakar SM, et al. Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. BMC Res Notes. 2018; 11:372. PMID: 29884220.
Article
21. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13:674–690. PMID: 27184417.
Article
22. Saitoh T, Mine T, Katoh M. Molecular cloning and expression of proto-oncogene FRAT1 in human cancer. Int J Oncol. 2002; 20:785–789. PMID: 11894125.
Article
23. Zhang Y, Han Y, Zheng R, Yu JH, Miao Y, Wang L, et al. Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC. Tumour Biol. 2012; 33:1437–1444. PMID: 22528942.
Article
24. Yost C, Farr GH 3rd, Pierce SB, Ferkey DM, Chen MM, Kimelman D. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell. 1998; 93:1031–1041. PMID: 9635432.
Article
25. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett. 1999; 458:247–251. PMID: 10481074.
Article
26. Li L, Yuan H, Weaver CD, Mao J, Farr GH 3rd, Sussman DJ, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 1999; 18:4233–4240. PMID: 10428961.
Article
27. Walf-Vorderwülbecke V, de Boer J, Horton SJ, van Amerongen R, Proost N, Berns A, et al. Frat2 mediates the oncogenic activation of Rac by MLL fusions. Blood. 2012; 120:4819–4828. PMID: 23074275.
Article
28. Jiang Y, Liu Y, Tan X, Yu S, Luo J. TPX2 as a novel prognostic indicator and promising therapeutic target in triple-negative breast cancer. Clin Breast Cancer. 2019; 19:450–455. PMID: 31494045.
Article
29. Yi K, Min KW, Wi YC, Kim Y, Shin SJ, Chung MS, et al. Wnt7a deficiency could predict worse disease-free and overall survival in estrogen receptor-positive breast cancer. J Breast Cancer. 2017; 20:361–367. PMID: 29285041.
Article
Full Text Links
  • ASTR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr